Allosource Inc., of Centennial, Colo., reported it has enrolled the first patient in a prospective, mulitcenter study to evaluate Prochondrix CR, a fresh cryopreserved osteochondral allograft, for the repair of focal articular cartilage defects in the knee. The study plans to enroll 80 patients in the U.S.
Epic Sciences Inc., of San Diego, said the New York State Department of Health has completed licensure to provide the Oncotype Dx AR-V7 Nucleus Detect test for patients with metastatic castration-resistant prostate cancer. The test helps determine which patients may benefit from androgen receptor signaling inhibitor therapy and which may benefit from chemotherapy. It is a circulating tumor cell-based, liquid biopsy test that is commercially available in the U.S. through Epic's partnership with Genomic Health.
Caesarea, Israel-based Icecure Medical Ltd. reported promising results from its first interventional radiology study. The early evaluation, presented at the 34th Annual European Association of Urology Congress in Barcelona, found the Prosense cryoablation system to be safe, effective and without serious adverse events in the treatment of small kidney tumors. Of 74 patients with 78 small kidney masses (= 4cm) treated, Prosense showed treatment success by lack of enhancement on CT or MRI in 93 percent of cases at 1 year follow-up. The minimally invasive Prosense uses liquid nitrogen technology to enable the treatment of benign and cancerous tumors by freezing, without surgery.
Itamar Medical Ltd., of Caesarea, Israel, launched the WatchPAT 300, the next-generation WatchPAT system for home sleep apnea testing. WatchPAT 300 utilizes peripheral arterial tone (PAT) and other signals to calculate true sleep time to accurately and reliably diagnose both obstructive and central sleep apnea. It has three points of contact without cumbersome nasal canula or chest belts to ensure patient ease of use.
Lonza Group Ltd., of Basel, Switzerland, launched the Lucetta 2 Luminometer, a single-tube system designed to simplify and accelerate mycoplasma detection in cell cultures. Pharmaceutical, biotechnology and academic researchers can now rely on this compact and portable instrument to run Lonza's Mycoalert mycoplasma detection assays and obtain reliable results within just 20 minutes.
Optovue Inc., a Fremont, Calif.-based developer of optical coherence tomography angiography (OCTA), reported the launch of its Angiowellness scan, which utilizes Optovue's Angiovue OCTA technology to assess and diagnose new pathologies in patients, including diabetic patients and those who may be at risk for glaucoma. Angiowellness combines structural information on retinal and ganglion cell thickness with objective metrics on retinal vasculature into one report. The patient-monitoring tool was designed to help eye care professionals offer a more comprehensive assessment of diabetic patients and glaucoma suspects.